[1] Fosang AJ, Last K, Stanton H, et al. Generation and novel distribution of matrix metalloproteinase-derived aggrecan fragments in porcine cartilage explants. J Biol Chem. 2000; 275(42):33027-33037. [2] Visse R, Nagase H.Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry.Circ Res. 2003;92(8):827-839. [3] 王玉彬,陈安民,郭风,等.基质金属蛋白酶家族在骨关节炎软骨组织中表达的研究[J].中国矫形外科杂志,2007,t:853-855.[4] 郭静,闫冰,李琪佳,等. 骨关节炎患者关节软骨及滑膜中MMP-9、IL-6的表达[J]. 第二军医大学学报, 2011,32(6): 672-676.[5] 李石胜,吴耀持,张峻峰,等.长针透刺膝骨关节炎模型大鼠滑膜组织中基质金属蛋白酶3的变化[J]. 中国组织工程研究与临床康复,2011,15(50):9415-9418.[6] 赵敬河,杨秋云,王冰.骨关节炎时内源性细胞因子及基质金属蛋白酶抑制因子1对关节软骨的影响[J].中国组织工程研究,2012, 16(15):2665-2668.[7] Fang J, Shing Y, Wiederschain D, et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model.Proc Natl Acad Sci U S A. 2000;97(8):3884-3889. [8] Brand K. Cancer gene therapy with tissue inhibitors of metalloproteinases (TIMPs). Curr Gene Ther. 2002;2(2): 255-271. [9] 李干,李奇,林荔军,等. IL-1、MMP-1及TIMP-1在兔骨性关节炎模型滑膜、软骨中的表达[J].实用医学杂志, 2011,27(15): 2721- 2723.[10] 高宁阳,曹月龙,刘婷, 等. C57黑鼠骨关节炎模型的关节病理积分与血清及滑膜中基质金属蛋白酶-3白细胞介素-1水平的相关性研究[J]. 中华风湿病学杂志,2010,3:195-19.[11] Haeusler G, Walter I, Helmreich M,et al. Localization of matrix metalloproteinases, (MMPs) their tissue inhibitors, and vascular endothelial growth factor (VEGF) in growth plates of children and adolescents indicates a role for MMPs in human postnatal growth and skeletal maturation. Calcif Tissue Int. 2005;76(5):326-335.[12] Henrotin Y, Addison S, Kraus V, et al. Type II collagen markers in osteoarthritis: what do they indicate?Curr Opin Rheumatol. 2007;19(5):444-450.[13] Eyre DR. Collagens and cartilage matrix homeostasis. Clin Orthop Relat Res. 2004;427:118-122. [14] Mahmoud RK, El-Ansary AK, El-Eishi HH, et al. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis. Ital J Biochem. 2005;54(3-4):248-257. [15] Green MJ, Gough AK, Devlin J, et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford). 2003;42(1):83-88. [16] Maeda S, Sawai T, Uzuki M, et al. Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis. Ann Rheum Dis. 1995;54(12):970-975.[17] Wu H, Du J, Zheng Q. Expression of MMP-1 in cartilage and synovium of experimentally induced rabbit ACLT traumatic osteoarthritis: immunohistochemical study. Rheumatol Int. 2008;29(1):31-36. [18] Freemont AJ, Hampson V, Tilman R, et al. Gene expression of matrix metalloproteinases 1, 3, and 9 by chondrocytes in osteoarthritic human knee articular cartilage is zone and grade specific. Ann Rheum Dis. 1997; 56(9):542-549. [19] Tolboom TC, Pieterman E, van der Laan WH, et al. Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Ann Rheum Dis. 2002;61(11):975-980.[20] Green MJ, Gough AK, Devlin J, et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford). 2003;42(1):83-88. [21] Tchetverikov I, Lard LR, DeGroot J, Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis. 2003;62(11):1094-1099. [22] Hamakawa H, Takemura M, Sato M, et al. Clinical significance of MMP-3 in patients with rheumatoid arthritis: comparison with other inflammatory markers(IL-6, IL-8). Rinsho Byori. 2003;51(1):13-18. [23] Fraser A, Fearon U, Reece R, et al. Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. Arthritis Rheum. 2001;44(9):2024-2028. [24] Bao JP, Chen WP, Feng J, et al. Leptin plays a catabolic role on articular cartilage. Mol Biol Rep. 2010;37(7):3265-3272. [25] Hulejová H, Baresová V, Klézl Z, et al. Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone. Cytokine. 2007;38(3):151-156. [26] Hsieh YS, Yang SF, Chu SC, et al. Expression changes of gelatinases in human osteoarthritic knees and arthroscopic debridement. Arthroscopy. 2004;20(5):482-488. [27] Li H, Li L, Min J, et al. Levels of metalloproteinase (MMP-3, MMP-9), NF-kappaB ligand (RANKL), and nitric oxide (NO) in peripheral blood of osteoarthritis (OA) patients. Clin Lab. 2012; 58(7-8):755-762. [28] Liacini A, Sylvester J, Li WQ, et al. Mithramycin downregulates proinflammatory cytokine-induced matrix metalloproteinase gene expression in articular chondrocytes. Arthritis Res Ther. 2005;7(4):R777-783. [29] Takaishi H, Kimura T, Dalal S, et al. Joint diseases and matrix metalloproteinases: a role for MMP-13. Curr Pharm Biotechnol. 2008;9(1):47-54.[30] Wernicke D, Seyfert C, Hinzmann B, et al. Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis. J Rheumatol. 1996; 23(4):590-595.[31] Wernicke D, Seyfert C, Gromnica-Ihle E, et al. The expression of collagenase 3 (MMP-13) mRNA in the synovial tissue is associated with histopathologic type II synovitis in rheumatoid arthritis. Autoimmunity. 2006;39(4):307-313. [32] Reboul P, Pelletier JP, Tardif G, et al. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis. J Clin Invest. 1996;97(9):2011-2019.[33] Fiedorczyk M, Klimiuk PA, Sierakowski S, et al. Correlations between serum matrix metalloproteinase (MMP-1, MMP-3, MMP-9, MMP-13) concentrations and markers of disease activity in early rheumatoid arthritis. Przegl Lek. 2005;62(12): 1321-1324. [34] Tang T, Muneta T, Ju YJ, et al. Serum keratan sulfate transiently increases in the early stage of osteoarthritis during strenuous running of rats: protective effect of intraarticular hyaluronan injection. Arthritis Res Ther. 2008;10(1):R13. |